GB2518873A — Bicyclic alkyne derivatives and uses thereof
Assigned to Agency for Science Technology and Research Singapore · Expires 2015-04-08 · 11y expired
What this patent protects
The present invention relates to certain compounds (e.g., imidazo[1,2-a]pyridine, imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine compounds) of the formula: wherein X1 and X2 are C or N; X3 and X4 are N or CR2; provided that at least 2 of X1, X2, X3 and X4 are N; the dashe…
USPTO Abstract
The present invention relates to certain compounds (e.g., imidazo[1,2-a]pyridine, imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine compounds) of the formula: wherein X1 and X2 are C or N; X3 and X4 are N or CR2; provided that at least 2 of X1, X2, X3 and X4 are N; the dashed line (along with the adjacent solid line) indicates the position of a single or double bond; R1 is hydrogen, optionally substituted phenyl or other substituents; Ring A is optionally substituted phenyl, 5-6-membered heteroaryl or 5,6-bicyclic heteroaryl; R2 is hydrogen, halogen, optionally substituted C1-6alkyl; optionally substituted carbocyclyl, -ORA or N(RB)2; RA and RB are hydrogen or substituents; that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the prevention and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, autoimmune diseases, metabolic diseases, and neurodegenerative diseases (e.g. Alzheimer's disease)).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.